We are live on ! Find out more
CMTA

Clementia Pharmaceuticals Inc.
CMTA

Delisted

CMTA was delisted on the 17th of April, 2019.

Back to rankings

0 hedge funds and large institutions have $0 invested in Clementia Pharmaceuticals Inc. in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 48 → 0 (-48)

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $732M → $0 (-$732M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 48

Holders
–
Holders Change
-48
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
48
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$272M
2
BBA
Baker Bros. Advisors
New York
-$97.2M
3
NMC
NEA Management Company
Maryland
-$70.7M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$53.5M
5
JP Morgan Chase
JP Morgan Chase
New York
-$41.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
– -$272M -10,425,225 Closed
BBA
2
Baker Bros. Advisors
New York
– -$97.2M -3,724,445 Closed
NMC
3
NEA Management Company
Maryland
– -$70.7M -2,707,734 Closed
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
– -$53.5M -2,050,389 Closed
JP Morgan Chase
5
JP Morgan Chase
New York
– -$41.7M -1,597,795 Closed
KLCMU
6
Kite Lake Capital Management (UK)
United Kingdom
– -$21.8M -836,070 Closed
Wellington Management Group
7
Wellington Management Group
Massachusetts
– -$21.8M -835,918 Closed
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
– -$17.8M -682,400 Closed
Tudor Investment Corp
9
Tudor Investment Corp
Connecticut
– -$10.8M -412,077 Closed
DCM
10
Driehaus Capital Management
Illinois
– -$10.7M -408,553 Closed
OM
11
Opaleye Management
Massachusetts
– -$10.4M -400,130 Closed
WIC
12
Water Island Capital
New York
– -$10M -383,907 Closed
IA
13
IndexIQ Advisors
New York
– -$7.31M -280,046 Closed
RSCM
14
Rock Springs Capital Management
Maryland
– -$7.18M -275,000 Closed
Millennium Management
15
Millennium Management
New York
– -$7.13M -273,286 Closed
GF
16
Gabelli Funds
New York
– -$6.96M -266,780 Closed
Grantham, Mayo, Van Otterloo & Co (GMO)
17
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
– -$6.76M -259,067 Closed
FI
18
Fosun International
China
– -$6.37M -244,826 Closed
BC
19
Birchview Capital
Vermont
– -$5.79M -222,000 Closed
EMPI
20
Elo Mutual Pension Insurance
Finland
– -$5.79M -222,000 Closed
Balyasny Asset Management
21
Balyasny Asset Management
Illinois
– -$5.13M -196,451 Closed
Federated Hermes
22
Federated Hermes
Pennsylvania
– -$4.96M -190,200 Closed
Ameriprise
23
Ameriprise
Minnesota
– -$4.01M -153,742 Closed
GCIA
24
Gabelli & Co Investment Advisers
New York
– -$3.33M -127,549 Closed
Jane Street
25
Jane Street
New York
– -$2.94M -112,846 Closed
1
2

CMTA Hedge Fund Activity: Q2 2019 in Review

0 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Clementia Pharmaceuticals Inc. (CMTA) for Q2 2019, worth a combined $0 — down 100% from $732M a quarter earlier.

Sellers outnumbered buyers: 48 funds closed out of CMTA and 0 opened new positions — a net loss of 48 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was OrbiMed, exiting entirely with an estimated $272M sold.

  • 0 institutional investors held Clementia Pharmaceuticals Inc. (CMTA) as of Q2 2019, down from 48 in Q1 2019.
  • Funds reported $0 of Clementia Pharmaceuticals Inc. stock for Q2 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Clementia Pharmaceuticals Inc. positions in Q2 2019 and 48 closed out, a net change of -48 holders.
  • The largest Clementia Pharmaceuticals Inc. seller in Q2 2019 was OrbiMed, an estimated $272M sold.

Based on aggregated 13F filings for Q2 2019.